Monitor for disease recurrence and progression post-surgery due to high relapse rates.
Employ molecular profiling to guide prognosis and therapeutic decisions.
Risks
High risk of metastasis at diagnosis (25–30%) and recurrence (20–40%) after surgery.
Intrinsic resistance to radiotherapy and chemotherapy limits treatment options.
Patient & Prescribing Data
Patients diagnosed with clear cell renal cell carcinoma, including those undergoing surgical and molecular diagnostic evaluation.
Current treatments are primarily surgical; molecular insights into SVs and enhancer hijacking may inform future targeted therapies and prognostic models.
Clinical Best Practices
Incorporate advanced genomic sequencing techniques to characterize SVs and 3D genome alterations in ccRCC.
Use integrative multi-omics approaches (WGS, Hi-C, ChIP-seq, RNA-seq) for comprehensive tumor profiling.
Consider molecular findings such as enhancer hijacking events in developing personalized treatment and prognostic strategies.
